CA3179167A1 - Antiviral compounds and method for treating rna viral infection, particularly covid-19 - Google Patents

Antiviral compounds and method for treating rna viral infection, particularly covid-19

Info

Publication number
CA3179167A1
CA3179167A1 CA3179167A CA3179167A CA3179167A1 CA 3179167 A1 CA3179167 A1 CA 3179167A1 CA 3179167 A CA3179167 A CA 3179167A CA 3179167 A CA3179167 A CA 3179167A CA 3179167 A1 CA3179167 A1 CA 3179167A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
ring
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3179167A
Other languages
English (en)
French (fr)
Inventor
Tai-Sen Soong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of CA3179167A1 publication Critical patent/CA3179167A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3179167A 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19 Pending CA3179167A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063001723P 2020-03-30 2020-03-30
US63/001,723 2020-03-30
US202063053908P 2020-07-20 2020-07-20
US63/053,908 2020-07-20
PCT/US2021/022976 WO2021202114A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19

Publications (1)

Publication Number Publication Date
CA3179167A1 true CA3179167A1 (en) 2021-10-07

Family

ID=77920792

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3179167A Pending CA3179167A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19
CA3179372A Pending CA3179372A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3179372A Pending CA3179372A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d

Country Status (11)

Country Link
US (2) US20210308137A1 (https=)
EP (2) EP4126846A1 (https=)
JP (2) JP2023520883A (https=)
KR (2) KR20230004550A (https=)
CN (1) CN116075502B (https=)
AU (2) AU2021249224A1 (https=)
BR (2) BR112022019558A2 (https=)
CA (2) CA3179167A1 (https=)
IL (2) IL296927B2 (https=)
TW (2) TW202203914A (https=)
WO (2) WO2021202114A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102641010B1 (ko) 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
JP2011515337A (ja) * 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター
KR20120044281A (ko) * 2009-04-17 2012-05-07 사일린 파마슈티칼스, 인크 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
US20110071136A1 (en) * 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc Novel tricyclic protein kinase modulators
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
JP5802676B2 (ja) * 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
TWI534148B (zh) * 2014-02-13 2016-05-21 生華生物科技股份有限公司 吡唑並嘧啶前藥及其使用方法
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
WO2021195126A1 (en) * 2020-03-24 2021-09-30 Burnet Michael W Anti-infective and anti-viral compounds and compositions
WO2021247367A1 (en) * 2020-06-02 2021-12-09 Yale University Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof

Also Published As

Publication number Publication date
CN116075502A (zh) 2023-05-05
EP4126846A1 (en) 2023-02-08
AU2021249224A1 (en) 2022-12-01
IL296927B1 (en) 2025-07-01
US20210308110A1 (en) 2021-10-07
WO2021202114A1 (en) 2021-10-07
WO2021202115A1 (en) 2021-10-07
EP4126845A4 (en) 2024-05-01
US20210308137A1 (en) 2021-10-07
BR112022019554A2 (pt) 2022-12-06
CA3179372A1 (en) 2021-10-07
CN116075502B (zh) 2024-04-12
KR20230004550A (ko) 2023-01-06
JP2023520882A (ja) 2023-05-22
TW202203915A (zh) 2022-02-01
AU2021248867A1 (en) 2022-12-01
IL296924A (en) 2022-12-01
US11696911B2 (en) 2023-07-11
EP4126845A1 (en) 2023-02-08
KR20230004549A (ko) 2023-01-06
JP2023520883A (ja) 2023-05-22
BR112022019558A2 (pt) 2022-12-06
IL296927B2 (en) 2025-11-01
IL296927A (en) 2022-12-01
TW202203914A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
US9487534B2 (en) Modulators of virus assembly as antiviral agents
TWI671298B (zh) 經取代之多環性吡啶酮衍生物及其前體藥物
AU2013342164A1 (en) Alternative uses for HBV assembly effectors
US11542257B2 (en) Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof
CA3150316A1 (en) ERK5 DEGRADING AGENTS USED AS THERAPEUTIC AGENTS IN CANCER AND INFLAMMATORY DISEASES
CA2965258A1 (en) Therapy for inhibition of single-stranded rna virus replication
CA2748719A1 (en) Anti-viral compounds, treatment, and assay
CA3179167A1 (en) Antiviral compounds and method for treating rna viral infection, particularly covid-19
BRPI0713488A2 (pt) derivados de 4-amino-3arilamino-6arilpirazolo[3,4-d]pirimidina, processos para a sua preparação e seu uso como substáncias ativas antivirais
WO2021207052A1 (en) Arginine methyltransferase 5 (prmt5) degraders and uses thereof
WO2020143798A1 (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
US11884653B2 (en) Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof
HK40086507B (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
HK40086507A (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
CN114159445B (zh) 筛选抑制新型冠状病毒感染的小分子药物的方法及其应用
CN120647663A (zh) 一种金刚烷修饰的喜树碱衍生物
CN118666868A (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250211

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250211

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250318

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250327

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250414

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250414

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250414

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250516

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251230

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251230